India’s Revised Biosimilar Guidelines Ready In A Month
This article was originally published in PharmAsia News
Executive Summary
A top Indian government official says revisions to the government’s regulatory guidelines for the development of biosimilars, which could herald the next wave of opportunity for the country's $15bn drug industry, should be ready in a month and will "address ethical questions."